Observational Study to Develop a Predictive Score for Adverse Events Post ERCP

NCT ID: NCT06776874

Last Updated: 2025-01-15

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 981 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-03-24
• Study Completion Date: 2025-12-31

Brief Summary

The main objective of the study is: the identification of independent factors associated with an increased risk of post-ERCP complications. Other objectives are: the development of a predictive model of events post-ERCP adverse events and its validation; geographic validation of a predictive model already published in the literature using data collected during the study and the evaluation of the rate of post-ERCP AEs in the centers involved in the study.

Detailed Description

Endoscopic retrograde cholangiopancreatography (ERCP) was described for the first time in 1968 and today is the pivotal procedure for the treatment of various biliopancreatic diseases. ERCP is associated with adverse events (AEs) such as post-ERCP pancreatitis (PEP), cholangitis and also with mortality.AEs related to therapeutic ERCP have been variably reported in several studies, with an estimated range of 4-30% for all AEs and 0.1-1% for overall mortality. In a systematic review of 21 studies prospective studies found an overall AE rate of 6.85% with mortality of 0.33%. PEP (3-15%) and bleeding (1-5%) are the two most common AEs, followed by cholangitis (1-5%) and perforation (1-2%). Several studies have attempted to identify potential risk factors for EAs ERCP-relati. Many of these studies are limited by the heterogeneity of definitions, the use of outdated criteria for the definition of AEs and by not large samples of patients. A more precise identification of the risk factors of EA related to ERCP is important so that preventive therapies can be introduced early and more effectively monitor individuals at increased risk. A recent retrospective study by Eduardo-Rodrigues Pinto et al. conducted on 1491 consecutive patients undergoing 1991 ERCP procedures, identified, based on pre- and intra-procedural covariables, risk factors related to patient and procedure for EA, in order to develop, through a multivariate logistic regression analysis, a predictive score estimating the likelihood of the occurrence of EA post-ERCP. This would allow a more correct information to the patient about the procedure and an optimization of the decision making of the physician in charge of the patient. Two two models, one considering only pre-procedural factors (model 1) and the other that considers both pre- and intra-procedural factors (model 2); both showed moderate predictive ability (AUC-ROC of 0.668 and 0.684 respectively). The score is based on data from patients from a single institution and has not been validated prospectively or externally to the population on which it was developed. The main objective of the study is: the identification of independent factors associated with an increased risk of post-ERCP complications. The secondary objectives are: the development of a predictive model of events post-ERCP adverse events and its validation; geographic validation of a predictive model already published in the literature [12] using data collected during the study and the evaluation of the rate of post-ERCP AEs in the centers involved in the study.

Conditions

Endoscopic Retrograde Cholangiopancreatography

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Patients undergoing ERCP according to normal clinical practice

The validation of the present predictive model and the one already published in the Literature will involve the simple application of the two models to a cohort of patients (so-called validation group), undergoing ERCP according to normal clinical practice; therefore, there will be no interventions that would may alter the patient's normal course of treatment.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Age >18 years
• Patients admitted with hepato-biliary-pancreatic disease or other pathological conditions that require treatment by ERCP
• Obtaining informed consent

Exclusion Criteria

• None

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lorenzo Lorenzo, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Lorenzo Fuccio, MD

Role: CONTACT

lorenzo.fuccio@aosp.bo.it

0512143338

Facility Contacts

Lorenzo Fuccio, MD

Role: primary

lorenzo.fuccio@aosp.bo.it

0512143338

Other Identifiers

ADVERCP

Identifier Type: -

Identifier Source: org_study_id